Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901177 | 0.88 | PKM (0.46) | HTTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL30916871 | 0.79 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6368861 | 0.79 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL20509746 | 0.77 | HTT (0.49) | HTTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL26936985 | 0.75 | MRGPRX1 (0.41) | HTTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13229696 | 0.73 | MEN1 (0.40) | HTTKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL22120503 | 0.72 | CHEK1 (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL10741472 | 0.71 | KMT2A (0.37) | HTTNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6707960 | 0.70 | EGLN1 (0.49) | HTTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9525340 | 0.70 | HAVCR2 (0.48) | HTTKDM4EALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6437132-B2 | INHIBITOR OF GONADOTROPIN RELEASING HORMONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | MIKI SHOKYO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6313301-B1 | CYCLIZATION; LUTEINIZING HORMONE RELEASING HORMONE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1004585-A1 | THIENOPYRIDINE DERIVATIVES, INTERMEDIATES THEREOF, AND PROCESS FOR PRODUCING THE BOTH | Takeda Chemical Industries, Ltd. (JP) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198384-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | HTT 675/4885NPC1 3638/4885RAB9A 3584/4885 |
| US-20020019529-A1 | Thienopyridine derivatives, their intermediates and production thereof | GNRHR, KISS1R, CYP19A1 | HTT 675/4885NPC1 3638/4885RAB9A 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.